Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

C-REGS2 - a Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients with Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

NCT03480698 is registered in ClinicalTrials.gov with Ever Neuro Pharma GmbH as lead sponsor.

NCT NCT03480698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03480698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
C-REGS2 - a Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients with Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke
Lead sponsor
Ever Neuro Pharma GmbH
Phase
Observational
Overall status
Completed
Start date
April 24, 2018
Completion date
July 15, 2024
Enrollment
1,851 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke